Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma.

CD44 CD44v6 immune cell infiltration melanoma microRNA

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
05 Nov 2019
Historique:
received: 09 08 2019
accepted: 21 10 2019
entrez: 20 11 2019
pubmed: 20 11 2019
medline: 20 11 2019
Statut: epublish

Résumé

The multistructural and multifunctional transmembrane glycoprotein CD44 is overexpressed in many tumors of distinct origin including malignant melanoma and contributes to a poor prognosis by affecting cell proliferation, cell migration, and also the sensitivity for apoptosis induction. Previous studies reported so far 15 CD44 regulatory microRNAs (miRs) in different cell systems. Using a novel method for miR affinity purification miR-143-3p was identified as most potent binder to the 3' untranslated region (UTR) of CD44. Overexpression of miR-143-3p in melanoma cells inhibits CD44 translation, which is accompanied by a reduced proliferation, migration and enhanced daunorubicin induced apoptosis of melanoma cells

Identifiants

pubmed: 31741714
doi: 10.18632/oncotarget.27305
pii: 27305
pmc: PMC6849650
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6509-6525

Déclaration de conflit d'intérêts

Conflicts of interest The authors declare that they have no competing interests.

Références

Int J Clin Exp Pathol. 2014 Sep 15;7(10):7182-90
pubmed: 25400815
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):667-675
pubmed: 30357969
Oncotarget. 2016 May 3;7(18):26866-78
pubmed: 27057628
Plant Methods. 2007 Oct 12;3:12
pubmed: 17931426
Nat Med. 2011 Feb;17(2):211-5
pubmed: 21240262
J Biol Chem. 2009 May 1;284(18):12432-46
pubmed: 19246453
Crit Rev Clin Lab Sci. 2002 Nov;39(6):527-79
pubmed: 12484499
Mol Cancer Res. 2011 May;9(5):637-47
pubmed: 21357442
Nucleic Acids Res. 2014 Apr;42(8):e66
pubmed: 24510096
Oncoimmunology. 2015 Mar 2;4(6):e1008805
pubmed: 26155421
Nat Protoc. 2016 Jan;11(1):22-36
pubmed: 26633129
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Clin Cancer Res. 1996 Mar;2(3):447-56
pubmed: 9816190
Int J Cancer. 1995 Jun 22;64(3):182-8
pubmed: 7542641
Med Sci Monit. 2016 Dec 06;22:4779-4785
pubmed: 27923017
Mol Pathol. 1998 Aug;51(4):191-200
pubmed: 9893744
Liver Int. 2018 Jul;38(7):1280-1291
pubmed: 29314711
Am J Transl Res. 2017 Jan 15;9(1):146-154
pubmed: 28123641
J Biol Chem. 2014 Nov 7;289(45):31121-35
pubmed: 25228695
Oncogene. 2017 May 11;36(19):2667-2679
pubmed: 27893706
J Natl Cancer Inst. 2014 Sep 12;106(10):null
pubmed: 25217579
BMC Cancer. 2015 Nov 16;15:903
pubmed: 26572077
J Pak Med Assoc. 2017 Oct;67(10):1524-1531
pubmed: 28955068
Cell Mol Neurobiol. 2016 Nov;36(8):1389-1397
pubmed: 26858153
Onco Targets Ther. 2018 Apr 27;11:2375-2385
pubmed: 29740213
Histochem Cell Biol. 1996 Sep;106(3):283-9
pubmed: 8897069
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11287-95
pubmed: 26617852
Mol Med Rep. 2016 Jun;13(6):5193-9
pubmed: 27121210
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
J Biol Chem. 2014 May 30;289(22):15340-9
pubmed: 24739387
Sci Rep. 2017 May 17;7(1):2042
pubmed: 28515423
Nucleic Acids Res. 2005 Nov 27;33(20):e179
pubmed: 16314309
Eur J Cancer. 1997 May;33(6):926-30
pubmed: 9291817
Obes Facts. 2017;10(6):569-583
pubmed: 29207395
Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45
pubmed: 12511867
Oncogene. 2014 Jan 30;33(5):665-70
pubmed: 23318432
PLoS One. 2016 Jul 27;11(7):e0159716
pubmed: 27463372
Anticancer Drugs. 2007 Apr;18(4):477-85
pubmed: 17351401
Cell Signal. 2014 Oct;26(10):2234-9
pubmed: 25025570
Mol Pathol. 1999 Aug;52(4):189-96
pubmed: 10694938
Biochem Biophys Res Commun. 2006 Aug 18;347(1):248-53
pubmed: 16824487
World J Gastroenterol. 2017 Apr 7;23(13):2337-2345
pubmed: 28428713
Biochem Biophys Res Commun. 2017 Jun 03;487(3):709-715
pubmed: 28442344
Cancer Res. 2012 Jul 15;72(14):3618-30
pubmed: 22552290
Front Cell Dev Biol. 2017 Mar 07;5:18
pubmed: 28326306
Oncotarget. 2016 Nov 29;7(48):80046-80058
pubmed: 27507056
Cancer Res. 1994 Mar 15;54(6):1561-5
pubmed: 7511044
Stem Cells Transl Med. 2015 Sep;4(9):1033-43
pubmed: 26136504

Auteurs

Johannes Fänder (J)

Institute of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Heike Kielstein (H)

Institute of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Maximilian Büttner (M)

Institute of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Peter Koelblinger (P)

Department of Dermatology, Paracelsus Medical University, Salzburg, Austria.

Reinhard Dummer (R)

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.

Marcus Bauer (M)

Institute for Pathology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Diana Handke (D)

Institute for Medical Immunology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Claudia Wickenhauser (C)

Institute for Pathology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Barbara Seliger (B)

Institute for Medical Immunology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Simon Jasinski-Bergner (S)

Institute of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.
Institute for Medical Immunology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

Classifications MeSH